All News
Filter News
Found 73,727 articles
-
Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
9/18/2020
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company and Bintai Kinden Corporation of Malaysia have signed an addendum binding the terms of the previously signed Memorandum of Understanding for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine.
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
9/18/2020
SpringWorks Therapeutics, Inc. announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.
-
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
9/18/2020
Autolus Therapeutics plc announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medical Oncology Virtual Congress 2020, beginning 18 September.
-
Beech Tree Labs selects Curavit Clinical Research for fully virtual COVID-19 clinical trial
9/18/2020
Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a promising Covid-19 therapy.
-
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
9/18/2020
Regeneron Pharmaceuticals, Inc. and Sanofi announced the presentation of positive results from the pivotal Phase 2 trial for the PD-1 inhibitor Libtayo® in patients with locally advanced basal cell carcinoma who had progressed on or were intolerant to hedgehog inhibitor therapy.
-
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
9/18/2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.
-
Disinfectant Sprays Market | Several Players have been able to Gain Profit from Heightened Sales of Disinfectant Sprays
9/18/2020
The use of disinfectant sprays is becoming a key part in managing in wide range of healthcare-associated infections in hospital and clinics settings.
-
Vaccine Glass Bottle Market | Rising Demand for Vaccine Glass Bottles from Pharmaceutical Companies for the Storage of COVID-19 Vaccine
9/18/2020
The ongoing COVID-19 pandemic is projected to generate prominent sales avenues in the global vaccine glass bottle market during the tenure of 2019 to 2029.
-
The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational, the company said.
-
Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, testified yesterday before the U.S. Senate Appropriations subcommittee on labor, health and human services, education and related agencies.
-
He also said they would be able to deliver 100 million doses to the U.S. government in the “first few months of 2021.”
-
BioSpace Global Roundup, Sept. 17
9/17/2020
Companies from across the globe provide updates on their businesses and pipelines. -
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.
-
With both autumn and flu season fast approaching, nearly everyone is wondering whether we will endure another round of illnesses that will rival that of last spring.
-
Acutus Medical Reports Second Quarter 2020 Financial Results
9/17/2020
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today reported financial results for its second quarter ended June 30, 2020.
-
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
9/17/2020
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos evaluating commercialization options for NLC-001 Worldwide
-
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With
9/17/2020
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, spoke to Jeremy Abbate, Publisher of Scientific American
-
Deloitte Names Tina Wheeler National Sector Leader for Health Care
9/17/2020
Deloitte has appointed Tina Wheeler as national sector leader for the health care practice in the U.S. effective immediately. Wheeler, a partner with Deloitte & Touche
-
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
9/17/2020
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors.
-
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
9/17/2020
Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 7,142,857 shares of common stock of the Company, at a price to the public of $2.80 per share,